Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

• Main Authors: David Monteith (Author), Emily C. Collins (Author), Corinne Vandermeulen (Author), Anne Van Hecken (Author), Eyas Raddad (Author), Joel C. Scherer (Author), David Grayzel (Author), Thomas J. Schuetz (Author), Jan de Hoon (Author)
• Format: Book
• Published: Frontiers Media S.A., 2017-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology of migraine headaches and represents a promising target for migraine treatment. The humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may be effective in migraine prophylaxis.Objectives: The p...